Last reviewed · How we verify
NCT04202614
Prognostic Role of Positron Emission Tomography and Computed Tomography Parameters in Stage I Lung Adenocarcinoma
trial in Stage I Pulmonary Adenocarcinoma in 58 participants. Completed in 31 January 2020.
31 January 2020
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 58 |
| Start date | 2 December 2019 |
| Primary completion | 31 January 2020 |
| Estimated completion | 31 January 2020 |
| Sites | 1 location across Italy |
Conditions studied
- Stage I Pulmonary Adenocarcinoma — all drugs for Stage I Pulmonary Adenocarcinoma →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
18 and older, any sex, with Stage I Pulmonary Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical and derived data from the preoperative computed axial tomography (CT) and Positron Emission Tomography (PET) of patients with pathological stage I pulmonary adenocarcinoma will be analyzed retrospectively, classified according to the current pathological classification IASLC / ATS / ERS of pulmonary adenocarcinoma, subjected to surgical treatment in our Operating Unit between August 2006 and July 2011. A follow-up will be performed on the patients enrolled in the study up to the date of death, and in any case no later than October 31, 2019
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic role of positron emission tomography and computed tomography parameters in stage I lung adenocarcinoma.
Carretta A, Bandiera A, Muriana P, Viscardi S, et al · · 2020 · cited 7× · PMID 32463388 · DOI 10.2478/raon-2020-0034
Verify or expand the search:
- PubMed search for NCT04202614
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04202614 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 10 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04202614.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing